6-Oxo-5,6,7,8-tetrahydronaphthalene-2-carbonitrile → 6-{4-[2-(2,1,3-Benzoxadiazol-5-yl)ethyl]-3-oxopiperazin-1-yl}-5,6,7,8-tetrahydronaphthalene-2-carbonitrile
반응식
[N:1]1[O:2][N:3]=[C:4]2[CH:9]=[C:8]([CH2:10][CH2:11][N:12]3[CH2:17][CH2:16][NH:15][CH2:14][C:13]3=[O:18])[CH:7]=[CH:6][C:5]=12.O=[C:20]1[CH2:29][CH2:28][C:27]2[CH:26]=[C:25]([C:30]#[N:31])[CH:24]=[CH:23][C:22]=2[CH2:21]1>>[N:1]1[O:2][N:3]=[C:4]2[CH:9]=[C:8]([CH2:10][CH2:11][N:12]3[CH2:17][CH2:16][N:15]([CH:20]4[CH2:29][CH2:28][C:27]5[CH:26]=[C:25]([C:30]#[N:31])[CH:24]=[CH:23][C:22]=5[CH2:21]4)[CH2:14][C:13]3=[O:18])[CH:7]=[CH:6][C:5]=12참가 물질
3
실험 절차
The title compound was prepared from 1-[2-(2,1,3-Benzoxadiazol-5-yl)ethyl]piperazin-2-one and 6-Oxo-5,6,7,8-tetrahydronaphthalene-2-carbonitrile following essentially the same procedure as Example 6. The product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA). LC-MS (IE, m/z): 402 [M+1]+.
후처리
- customThe product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA)